Impact BioMedical Statistics
Share Statistics
Impact BioMedical has 11.50M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 11.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 5.75K |
| FTD / Avg. Volume | 11.62% |
Short Selling Information
The latest short interest is 1.05K, so 0.01% of the outstanding shares have been sold short.
| Short Interest | 1.05K |
| Short % of Shares Out | 0.01% |
| Short % of Float | 0.02% |
| Short Ratio (days to cover) | 0.02 |
Valuation Ratios
The PE ratio is -0.62 and the forward PE ratio is null.
| PE Ratio | -0.62 |
| Forward PE | null |
| PS Ratio | 6.07 |
| Forward PS | null |
| PB Ratio | 1.65 |
| P/FCF Ratio | -1.47 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Impact BioMedical Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.6, with a Debt / Equity ratio of 0.44.
| Current Ratio | 1.6 |
| Quick Ratio | 1.6 |
| Debt / Equity | 0.44 |
| Total Debt / Capitalization | 30.59 |
| Cash Flow / Debt | -2.49 |
| Interest Coverage | 7.34 |
Financial Efficiency
Return on equity (ROE) is -2.66% and return on capital (ROIC) is null%.
| Return on Equity (ROE) | -2.66% |
| Return on Assets (ROA) | -1.66% |
| Return on Capital (ROIC) | null% |
| Revenue Per Employee | - |
| Profits Per Employee | - |
| Employee Count | 1 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | - |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by -99.5% in the last 52 weeks. The beta is 0, so Impact BioMedical 's price volatility has been lower than the market average.
| Beta | 0 |
| 52-Week Price Change | -99.5% |
| 50-Day Moving Average | 2.25 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 34.03 |
| Average Volume (20 Days) | 49.46K |
Income Statement
| Revenue | n/a |
| Gross Profit | - |
| Operating Income | - |
| Net Income | - |
| EBITDA | - |
| EBIT | n/a |
| Earnings Per Share (EPS) | null |
Balance Sheet
The company has - in cash and - in debt, giving a net cash position of 0.
| Cash & Cash Equivalents | - |
| Total Debt | - |
| Net Cash | 0 |
| Retained Earnings | - |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was - and capital expenditures -, giving a free cash flow of -.
| Operating Cash Flow | - |
| Capital Expenditures | - |
| Free Cash Flow | - |
| FCF Per Share | -0.02 |
Margins
Gross margin is 100%, with operating and profit margins of 46.43% and -980.22%.
| Gross Margin | 100% |
| Operating Margin | 46.43% |
| Pretax Margin | -980.22% |
| Profit Margin | -980.22% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IBO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for IBO.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |